



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428      **Phone:** (800) 745-7318

## Headache Therapy (Butalbital Combination Agents) Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Medication requested

- |  |   |
|--|---|
| <input type="checkbox"/> butalbital/acetaminophen (25 mg/325 mg)   | <input type="checkbox"/> butalbital/acetaminophen/caffeine/codeine (50 mg/300 mg/40 mg/30 mg)                                     |
| <input type="checkbox"/> butalbital/acetaminophen (50 mg/300 mg)   | <input type="checkbox"/> butalbital/acetaminophen/caffeine/codeine (50 mg/325 mg/40 mg/30 mg) > 20 units/month, < 18 years of age |
| <input type="checkbox"/> butalbital/acetaminophen (50 mg/325 mg)   | <input type="checkbox"/> butalbital/acetaminophen/caffeine capsule (50 mg/325 mg/40 mg)   |
| <input type="checkbox"/> butalbital/acetaminophen/caffeine (50 mg/300 mg/40 mg)  | <input type="checkbox"/> butalbital/acetaminophen/caffeine tablet (50 mg/325 mg/40 mg) > 20 units/month, < 18 years of age        |
| <input type="checkbox"/> butalbital/acetaminophen/caffeine capsule (50 mg/325 mg/40 mg)                                    | <input type="checkbox"/> butalbital/acetaminophen/caffeine solution   |
| <input type="checkbox"/> butalbital/acetaminophen/caffeine tablet (50 mg/325 mg/40 mg) > 20 units/month, < 18 years of age | <input type="checkbox"/> Other butalbital agent _____   |
| <input type="checkbox"/> butalbital/acetaminophen/caffeine solution  |   |

Quantity requested per month \_\_\_\_\_

Dose, frequency, and duration of medication requested \_\_\_\_\_

Indication (Check all that apply.)

- Cluster headache. Frequency of headaches (number/month) \_\_\_\_\_
- Migraine headache. Frequency of migraine attacks (number/month) \_\_\_\_\_
- Tension headache. Frequency of headaches (number/month) \_\_\_\_\_
- Other. Specify pertinent medical history, diagnostic studies, and/or laboratory tests. \_\_\_\_\_

### Section I. Please complete for butalbital agent requests exceeding quantity limits or for members < 18 years of age.

- For migraine headache requests, has the member tried two triptans?  
 Yes. Please list the drug names and outcomes below.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response

Briefly describe the details of adverse reaction or inadequate response.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response

Briefly describe the details of adverse reaction or inadequate response.

No. Explain why triptans are not appropriate in this member.

2. For migraine headache requests, has the member tried an oral calcitonin gene-related peptide (CGRP) inhibitor?

Yes. Please list the drug name and outcome below.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response

Briefly describe the details of adverse reaction or inadequate response.

No. Explain why oral CGRP inhibitors are not appropriate in this member.

3. For both migraine and tension headache requests, is the member currently receiving prophylaxis?

Yes. Please specify.

Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_

Drug name \_\_\_\_\_ Dose and frequency \_\_\_\_\_

No. Explain why prophylaxis is not appropriate in this member.

4. Is the member under the care of a neurologist?  Yes  No

5. Please list any other prior headache therapy trials. Please list the drug names and outcomes below.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

---

**Section II. Please also complete for requests for butalbital/aspirin/caffeine capsule and butalbital 50 mg/acetaminophen 325 mg/caffeine 40 mg capsule.**

Has the member tried butalbital 50 mg/acetaminophen 325 mg/caffeine 40 mg tablet?

Yes. Please list the dates/duration of use and outcome below.

Dates/duration of use \_\_\_\_\_  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Explain why butalbital 50 mg/acetaminophen 325 mg/caffeine 40 mg tablet is not appropriate in this member.

---

---

**Section III. Please also complete for requests for all other butalbital agents that require PA and requests for codeine-containing products for members < 12 years of age.**

Please provide clinical rationale for the requested agent. Please address the need for the requested formulation over the covered agents, dosage formulation over conventional dosage forms, or use in the requested age group as appropriate.

---

---

---

---

**Section IV. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

---

---

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

\* Required

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_